XRAY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002, for DENTSPLY International Inc. (now DENTSPLY SIRONA Inc.). The company is a global manufacturer of dental products, including large equipment, consumables, and precious metal alloys. The reporting period includes the impact of significant acquisitions, most notably the Degussa Dental Group, and reflects the adoption of new accounting standards regarding goodwill (SFAS 142).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 43.4% in Q3 and 45.0% for the nine-month period. This growth was driven primarily by acquisitions (Degussa Dental, Austenal) and favorable currency translation, with underlying base business growth of 6.2% in Q3 and 7.4% for the nine months.
• Margin Compression: Gross margins declined slightly (49.3% vs. 52.2% in Q3) due to the inclusion of precious metal alloy sales from Degussa Dental, which have lower margins. Excluding precious metals, margins improved to 55.7% due to product mix and operational efficiencies.
• Accounting Changes: The company adopted SFAS 142, discontinuing goodwill amortization effective January 1, 2002. This contributed to lower SG&A expenses as a percentage of sales (32.5% in Q3 2002 vs. 34.7% in Q3 2001).
• Restructuring: The company recorded $2.8 million in restructuring and other income for the nine months ended Sept 30, 2002, largely due to changes in estimates on prior plans and an insurance settlement gain from a 2001 fire. This contrasts with $5.5 million in restructuring costs in the same period of 2001.
• Investing Activity: Net cash used in investing activities was $65.6 million for the nine months, primarily due to $51.1 million in acquisition costs and $39.8 million in capital expenditures.

Guidance, Outlook, and Risks

• Full Year Guidance: Management maintains its 2002 year-end earnings guidance of $1.80 - $1.82 per share of fully diluted common stock.
• PracticeWorks Investment: The company exchanged its preferred stock in PracticeWorks for cash, common stock, and warrants. A significant decline in PracticeWorks' stock price in October 2002 could negatively impact Q4 earnings by approximately $0.02 - $0.03 per share due to mark-to-market adjustments on the warrants.
• Antitrust Litigation: The Department of Justice trial regarding the Trubyte Division's distribution practices concluded in September 2002, with a decision expected in late 2002. The company believes the risk of a material adverse effect is remote.
• Liquidity: The company has $382.3 million in unused lines of credit and expects to finance future requirements through operations and existing credit facilities. A payment of up to $10 million is expected in early 2003 related to the final consideration for the Degussa Dental acquisition.

Investor Verification Checklist

• Acquisition Integration: Verify the realization of synergies from the Degussa Dental and Austenal acquisitions, particularly in the European market where sales grew 119.3%.
• Precious Metals Exposure: Monitor the volatility of precious metal prices and their impact on reported gross margins, as this segment dilutes overall margin percentages.
• Antitrust Outcome: Track the final ruling in the DOJ antitrust case regarding the Trubyte Division, as penalties or mandated changes could impact future operations.
• PracticeWorks Valuation: Assess the fair value of the remaining PracticeWorks common stock and warrants, as fluctuations directly impact "Other expense (income)" and comprehensive income.
• Debt Levels: Review the company's ability to service its $773 million long-term debt, noting that a portion of the increase is due to foreign exchange fluctuations rather than new borrowing.